Table 2 Demographic and baseline characteristics from the integrated population of the two phase III HIV-DSP studies
| Â | Â | NGX-4010 | NGX-4010 | Â | Control | Control |
|---|---|---|---|---|---|---|
NGX-4010 total | 30 minutes | 60 minutes | Control total | 30 minutes | 60 minutes | |
(n = 482) | (n = 239) | (n = 243) | (n = 215) | (n = 100) | (n = 115) | |
Age, mean (SD), years | 49 (8) | 50 (9) | 49 (8) | 50 (8) | 49 (8) | 50 (9) |
Male, n (%) | 426 (88) | 205 (86) | 221 (91) | 193 (90) | 90 (90) | 103 (90) |
White, n (%) | 315 (65) | 156 (65) | 159 (65) | 144 (67) | 68 (68) | 76 (66) |
Duration of pain, mean (SD), years | 5.8 (3.9) | 5.6 (3.7) | 6.0 (4.1) | 5.6 (4.1) | 5.9 (3.9) | 5.4 (4.4) |
Baseline NPRS score, mean (SD) | 6.0 (1.6) | 6.0 (1.6) | 6.0 (1.5) | 5.9 (1.5) | 6.0 (1.5) | 5.8 (1.5) |
Receiving concomitant neuropathic pain medication at study entry,* n (%) | 339 (70) | 180 (75) | 159 (65) | 143 (67) | 72 (72) | 71 (62) |
Receiving Ntox antiretroviral therapy at baseline,†n (%) | 52 (11) | 25 (10) | 27 (11) | 18 (8) | 8 (8) | 10 (9) |
CD4 count, mean x106/l (SD) | 419 (242) | 437 (235) | 402 (247) | 468 (314) | 479 (291) | 458 (334) |
Viral load, HIV RNA copies/ml, median | 400 | 400 | 400 | 400 | 400 | 400 |
(range) | (40–5,510,520) | (40–610,677) | (40–5,510,520) | (40–664,583) | (40–664,583) | (40–460,000) |